These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20937778)

  • 1. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.
    Pasipanodya J; Gumbo T
    Antimicrob Agents Chemother; 2011 Jan; 55(1):24-34. PubMed ID: 20937778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
    Gumbo T
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
    Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.
    Gumbo T; Dona CS; Meek C; Leff R
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3197-204. PubMed ID: 19451303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
    Srivastava S; Gumbo T
    Curr Pharm Des; 2011; 17(27):2881-8. PubMed ID: 21834761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.
    Liu Y; Moodley M; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0140122. PubMed ID: 36877034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
    Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Van Schalkwyk M; Bekker A; Decloedt E; Wang J; Theron GB; Cotton MF; Eke AC; Cressey TR; Shapiro DE; Bacon K; Knowles K; George K; Browning R; Chakhtoura N; Rungruengthanakit K; Wiesner L; Capparelli EV; Stek AM; Mirochnick M; Best BM;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0073723. PubMed ID: 37882552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.
    Hall RG; Leff RD; Gumbo T
    Pharmacotherapy; 2009 Dec; 29(12):1468-81. PubMed ID: 19947806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
    Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
    Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
    Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.
    Jeena PM; Bishai WR; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2011 Feb; 55(2):539-45. PubMed ID: 21098246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic considerations in use and development of antituberculosis drugs.
    Davies G
    Cold Spring Harb Perspect Med; 2014 Sep; 5(1):a021170. PubMed ID: 25237145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs.
    Budha NR; Lee RE; Meibohm B
    Curr Med Chem; 2008; 15(8):809-25. PubMed ID: 18393850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.